Aposense Pipeline: From Platform to Products

More documents

Recommendations

Info

ATT-11T showed superior efficacy Melanoma Model A375 Ovarian Carcinoma Model OVCAR Tumor size (mm 3 ) 4000 Human 3500 melanoma implanted in 3000 mice Non-Treated (Control group) Irinotecan (75 X 3 mg) Tumor size (mm 3 ) Control-vehicle 1000 CPT-11 3x18mg/kg 900 ATT-11T 3x20mg/kg 800 Non-Treated (Control group) Irinotecan (3 X 18 mg) 2500 2000 700 600 500 1500 400 1000 500 0 10 15 20 25 30 35 40 45 50 55 60 ATT-11T (5 X 9 mg) 300 200 100 0 ATT-11T (3 X 20 mg) 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 Tx End Tx End
ATT-11T Preliminary Safety MTD studies: daily administration in rats (n=3 per group); no <strong>to</strong>xicity observed Weight (% from baseline) 110 105 100 ATT-11T, 200 mg/Kg, PO 95 90 85 80 Irinotecan, 90 mg/Kg, IP 75 70 1 2 3 4 5 Days Irinotecan ATT-11T Weight at day 5(%) 77-96 99-102 Diarrhea 2 / 3 None
Page 1 and 2: Aposense Presentation at the UBS Gl
Page 3 and 4: Apoptosis, a biological process inv
Page 5 and 6: MISSION Translate Apoptosis to Pati
Page 8 and 9: Molecular Imaging First sight of di
Page 10 and 11: Molecular Imaging of Apoptosis: Cli
Page 12 and 13: Commercialization Partner World’s
Page 14 and 15: N Targeting apoptosis Extending pha
Page 16 and 17: ATT-11T: Prolonging SN-38 Half-life
Page 20 and 21: TEVA agreement • TEVA collaborati
Page 22 and 23: ATT-GEM potent in resistant cells h
Page 24 and 25: ATT-LD Long-acting levodopa for tre
Page 26 and 27: ATT-LD Significantly Extends Levodo
Page 28 and 29: New Product Initiation Process Iden
Page 30 and 31: Financial Information Shareholder B
Page 32: Thank you.

Aposense Pipeline: From Platform to Products

Create successful ePaper yourself

Delete template?

Save as template?